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ABSTRACT
Uveitic cystoid macular edema (UME) is an important cause of visual morbidity among patients with both
infectious and non-infectious uveitis. UME may be associated in more than 30% cases of active uveitis.
However, even patients with minimal features of intraocular inflammation may develop recurrent or chronic
UME. Therefore, the evaluation and management of UME in patients with uveitis may be challenging. A
number of vitreoretinal pathologies may result in UME and accumulation of fluid in the intra- or subretinal
space. These need to be carefully distinguished from each other so that appropriate management can be
initiated. All types of uveitis, including anterior uveitis (where the primary site of inflammation is not in the
posterior segment) can present with UME. Other conditions such as diabetes, and surgery, can present with
macular edema. This index review highlights various differential diagnoses of UME and provides illustrative
case examples with multimodal imaging evaluation.
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Uveitic cystoid macular edema (UME) is a major
cause of visual morbidity among patients with both,
infectious and non-infectious uveitis. More than 30%
patients with uveitis can develop serious sight-threa-
tening vision loss due to UME.1–3 The prevalence of
UME is more common with posterior uveitis.
However, any form of inflammation in the eye,
including anterior uveitis (AU), can lead to UME.
Chronic forms of uveitis, such as birdshot chorioreti-
nopathy, sarcoidosis, and Behcet’s disease are highly
likely to develop persistent and often refractory UME.
Since chronic UME is a significant cause of perma-
nent visual impairment, it needs careful evaluation,
and identification of the pro-inflammatory factors
leading to development of UME. Recurrent or non-
responsive UME could indicate breakdown of the
blood–retinal barrier, increased local inflammatory
mediators, vascular compromise/hyperpermeability,
or dysfunction of the retinal pigment epithelial
(RPE) pump mechanism. It is relevant to ascertain
the cause of UME, recognize specific clinical entities,
and identify UME associated with idiopathic uveitis,
so that appropriate therapy can be instituted. Early
diagnosis and therapy prevent long-term photorecep-
tor and RPE cell damage, and help in preserving
visual acuity in these patients.1,2
Among patients with uveitis, there may be other
causes leading to presence of intra- or subretinal fluid.
For instance, inflammatory macular edema may occur
in patients after surgical intervention (such as post-cat-
aract surgery macular edema). There may be other con-
ditions that mimic UME, such as drug-induced
maculopathies. Rarely, retinal dystrophies may be asso-
ciated with ocular inflammation and UME. Therefore, a
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complete history, examination, and evaluation using
multimodal imaging including optical coherence tomo-
graphy (OCT), fluorescein angiography (FA), and other
tools is necessary to accurately diagnose UME.
In the index review, various differential diagnoses
of UME including uveitic and non-uveitic causes have
been described with illustrative case examples. The
relevance of various imaging techniques in the eva-
luation of UME such as FA, OCT, and wide-field
imaging has been thoroughly explained.
ROLE OF IMAGING IN THE DIFFERENTIAL
DIAGNOSIS OF MACULAR EDEMA
UME may be diagnosed clinically using macular con-
tact lens or careful slit-lamp biomicroscopy. However,
in the era of advanced imaging diagnostics, various
imaging tools such as OCT and FA are preferred for
making an accurate diagnosis. OCT has distinct
advantages such as its ability of detecting concomi-
tant pathologies such as abnormal vitreomacular trac-
tions, epiretinal membranes, and macular
detachment. FA, on the other hand, helps in the eva-
luation of macular perfusion and regularity of the
foveal avascular zone.
Fluorescein Angiography
FA is very useful in determining the true location of
the inflammation, disease activity, and involvement
of retinal vasculature and optic disc. FA helps in the
detection of level and severity of intraocular inflam-
mation, presence of active choroiditis/retinitis
lesions, and quantification of retinal vascular (venu-
lar/arteriolar or capillary) leakage. These findings aid
the clinician in arriving at an etiological diagnosis.
Thus, FA plays a central role in the management of
uveitis and various other conditions that mimic ocular
inflammations such as masquerade syndromes (for
example, intraocular lymphoma). Leakage on FA can
be further characterized as macular or peripheral and
based upon the vessel of origin, it can be classified as
small, medium, or large vessel leakage.3–5
Recognition of perifoveal/macular leakage is rele-
vant because the status of the macular vasculature can
have a direct relationship with the visual morbidity.
Leakage may be restricted to the region of the foveal
avascular zone or it may extend well beyond to
involve the parafoveal region. In the early phase of
the FA, macular leakage may have a subtle appear-
ance as a faint hyperfluorescence. Therefore, venous
or late phase of the FA is relevant to determine the
exact extent of leakage and hyperfluorescence. An
assessment of the late FA frames can help in deter-
mining the presence of vascular as well as macular
leakage suggestive of UME. Angiographic presence of
leakage and UME is an indicator of ongoing inflam-
mation and breakdown of blood–retinal barrier,
requiring treatment.
Attempts have been made to determine the rela-
tionship between fluorescein angiographic leakage at
the macula and the visual acuity. Studies have shown
that presence of angiographic UME at the initial visit
may be related to the visual prognosis in entities such
as Behcet’s disease.6 Other features on FA such as
retinal vascular leakage and optic disc hyperfluores-
cence are also significantly associated with worse
initial visual acuity.7 Hence, at baseline, assessment
using FA not only helps in determining disease activ-
ity, but also in the prediction of visual recovery fol-
lowing treatment of UME.
The introduction of ultra-wide field (UWF) FA has
revolutionized the management of various conditions
such as posterior uveitis and diabetic retinopathy.
UWF FA provides significant additional information
over conventional FA helping in changing manage-
ment decisions such as modifications of therapeutic
interventions. In the context of UME, UWF FA ima-
ging has been shown to be useful in correlating vas-
cular leakage with macular thickness. Eyes with
peripheral vascular leakage on UWF FA are likely to
have UME at baseline, requiring more aggressive
therapy.8 Similarly, another study of 82 uveitis
patients undergoing UWF FA showed that peripheral
leakage is associated with central macular leakage.9
UWF FA is very helpful in determining the presence
of occlusive vasculitis and for the quantification of the
true extent of the capillary non-perfusion. Areas of
retinal ischemia and neovascularization can be easily
identified using UWF FA, aiding in decision for tar-
geted laser photocoagulation.10–12 In summary, FA
imaging greatly aids in the detection and follow-up
of UME related to uveitis as well as other diseases
affecting the retinochoroidal tissue.
Optical Coherence Tomography
OCT provides in vivo near-histological cross-sectional
images of the retina and the choroid permitting
detailed analysis of the pathology affecting various
structural layers. OCT allows non-invasive monitor-
ing of the retinal thickness and edema, along with
presence of intra- or subretinal fluid that occurs due
to breakdown of the blood–retinal barrier in various
pathologies. OCT permits highly reproducible moni-
toring of the retinochoroid during treatment of UME.
Precise monitoring of the retinal thickness is possible
by using follow-up scan protocols that capture images
of the exact same location as the previous visit.
Presence of significant retinal thickening with edema
and fluid is associated with poor visual acuity.3–5,13
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With the introduction of higher resolution OCT such
as spectral-domain OCT (SD-OCT), it has become pos-
sible to further characterize the type andmorphology of
edema and UME, and improve the prediction of visual
recovery in these patients. Using high-resolution OCT, it
is possible to document and measure the central retinal
thickness and the area of serous macular detachment
with greater precision. In addition, better delineation of
outer retinal layers such as the external limiting mem-
brane, and the ellipsoid and myoid zones is possible
with the OCT. The integrity of the outer retinal layers
and RPE is directly correlated with the central visual
acuity recovery. Disruption of the outer retinal layers
can seriously compromise the visual recovery despite
resolution of the intra- or subretinal fluid.14,15
OCT has become the gold standard in the diagnosis
of UME. Using OCT, it is possible to classify the
patterns of UME qualitatively. In 2004,
Markomichelakis et al. performed a cross-sectional
study in 84 eyes of 60 patients with UME. The authors
observed three patterns of UME, i.e. diffuse pattern,
cystoid macular edema (CME), and serous retinal
detachment.13 Eyes with cystoid type of edema had
a higher probability of visual improvement.16 In addi-
tion, OCT can aid in the detection of additional con-
ditions leading to higher macular thickness in uveitis,
such as presence of concomitant epiretinal mem-
branes or vitreomacular traction, as well as presence
of inflammatory choroidal neovascular membranes.
More than 30% patients with UME may have asso-
ciated epiretinal membranes.13
Various studies have compared the utility and advan-
tages of OCT over FA in the management of UME.
Antcliff et al.17 compared OCT and FA in over 100
patients with UME. The authors observed that OCT
was as effective as FA in detecting UME. However,
OCT is superior in identification of the axial distribution
of fluid; for instance, detection of subretinal fluid (SRF) is
possible using OCT. OCT has a high sensitivity and
specificity in detection of UME compared to FA. Thus,
while FA and OCT are both very useful techniques in
diagnosing UME, the two modalities complement each
other and provide a different set of information that
helps in comprehensive evaluation of the patient. When
used independently, there may be certain discrepancies
in the detection of fluid.18 Therefore, a combination of
OCT and FA may provide highly precise, reproducible
and comprehensive evaluation of the UME (both quanti-
tative and qualitative) in eyes with uveitis.
COMMON CAUSES OF UVEITIC MACULAR
EDEMA
Anterior Uveitis
The classification of uveitis proposed by the first
international workshop on standardization of Uveitis
Nomenclature (SUN) defines an AU as an ocular
inflammatory process having the anterior chamber
of the eye as primary site of inflammation.19 Patients
affected by AU can develop UME though, by defini-
tion, there is no posterior segment disease. Even when
detected, the presence of UME does not change the
classification of AU, because it is considered a com-
plication and not the primary location of the inflam-
matory process.
HLA-B27-associated acute AU is the most common
cause of AU representing the 18–32% and the 6–13%
of all AU cases in western countries and in Asia,
respectively. The incidence of UME among HLA-B27
uveitis patients has been reported to be 6–30%
depending on the studied population.20 While HLA-
B27 AU is characterized by specific features and a
higher incidence of certain complications, the inci-
dence of UME seems to be similar in HLA-B27- and
non-HLA-B27-related AU.21 Viral induced-AU how-
ever seem to be less commonly complicated by UME,
with the presence of fluid in the macular area being
rarely reported in these entities.22,23 Finally, UME is
virtually absent in Fuchs’ iridocyclitis, a specific type
of AU mainly caused by rubella virus infection, thus
helping in the differential diagnosis of Fuchs’s with
other similar entities.24
No significant differences in the incidence of UME
between the normal population and uveitic eyes
undergoing cataract surgery after 3 months without
signs of active inflammation have been reported.25
However, several studies suggest that eyes affected
by uveitis, including anterior form of uveitis, are
more likely to develop UME or to have UME recur-
rence after cataract surgery.25–27 This is particularly
true for chronic forms of AU, such as uveitis related
to juvenile idiopathic arthritis, that has been reported
to have up to 55% incidence of UME after cataract
surgery.28
Intermediate Uveitis and Pars Planitis
The SUN classifies intermediate uveitis (IU) as an
inflammatory condition where the vitreous is the
major site of inflammation. Often the primary vitr-
eous involvement is accompanied by peripheral vas-
cular sheathing and UME.19 The majority of cases of
IU are of idiopathic etiology and are usually referred
as pars planitis. This is a non-granulomatous bilateral
uveitis occurring in young individuals with a higher
prevalence between 15 to 35 years of age. As the
majority of pediatric patients with uveitis have an
indeterminate cause (with no systemic involvement),
pars planitis is most often diagnosed in this patient
population. However, the association of IU with sev-
eral autoimmune and infectious diseases such as mul-
tiple sclerosis, sarcoidosis, tuberculosis, and Lyme
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disease has been reported in the literature.29 It is
imperative to suspect multiple sclerosis in patients
with IU, to avoid delays in the diagnosis of the sys-
temic disease. Baseline neuroimaging be performed to
rule out white matter lesions of the central nervous
system.
IU is usually a benign inflammatory condition but
its complications if untreated can lead to severe visual
loss. UME, with an incidence ranging from 12% to
51% depending on the studied population, is the
most common cause of visual loss in these entities.30
The detection of a visual impairing macular edema
plays a key role in the management of IU. In fact,
while cases with IU can be managed with observation
alone (if the inflammation is mild), treatment needs to
be initiated promptly in the presence of vision-threa-
tening complications such as UME.29
Retinal Vasculitis
Retinal vasculitis is characterized by inflammation of
the retinal venules, arterioles and/or capillaries with
perivascular sheathing or cuffing, vascular leakage,
and/or occlusion. There may be signs of retinal ische-
mia, including cotton-wool spots and intra-retinal
hemorrhages, as well as UME. Retinal vasculitis may
be associated with various infectious etiologies such
as tuberculosis, syphilis, Lyme’s disease, cat-scratch
disease, among others, and non-infectious etiologies
such as sarcoidosis, Birdshot chorioretinopathy,
Behcet’s disease, as well as IU /pars planitis.31–33
Retinal vasculitis may be associated with type III
hypersensitivity reaction and focal, segmental or dif-
fuse retinal perivascular proliferation of lymphoplas-
macytic infiltrates.31 Retinal vasculitis is also
characterized by a breakdown of blood–retinal barrier
secondary to intraocular or systemic inflammation
resulting in macular edema and intra-/subretinal
fluid accumulation. Increased expression of cell adhe-
sion molecules along retinal vessels and blood–retinal
barrier cells plays an important role in inflammatory
cell recruitment. Excessive inflammation may also
result in an occlusive form of vasculitis characterized
by development of retinal neovascularization and
high rates of ocular complications.34
Although there is a large pathological diversity
among the retinal vasculitis etiologies, the manifesta-
tions of inflammatory changes resemble inmanyways.
Patients with active retinal vasculitis may have
reduced visual acuity due to presence of central macu-
lar edema.35 Retinal thickening can be observed on FA
as leakage of dye in the macula or presence of a diffuse
hyperfluorescence increasing toward the late phase.36
This must be differentiated from an increase in the
macular leakage following laser photocoagulation per-
formed for retinal ischemia. Common diseases
associated with retinal vasculitis and UME include
intraocular tuberculosis,37,38 Behcet’s disease,39
Birdshot chorioretinopathy,40 and sarcoidosis.41,42
Non-inflammatory retinal vein occlusion (either
central or branch retinal vein occlusion) associated
with macular edema closely parallels inflammatory
retinal vascular occlusion. However, both central
and branch retinal vein occlusions (CRVO and
BRVO) are not associated with clinically appreciable
vascular sheathing, vitritis, or other signs of inflam-
mation. FA does not show early vascular leakage, but
may show only late staining of the occluded vessels.34
Choroiditis and Chorioretinitis
When the primary site of inflammation is the choroid
or the retina, the uveitis is typically classified as chor-
oiditis or chorioretinitis.19 These entities can have an
autoimmune or an infectious cause with specific fea-
tures characterizing the different forms and helping in
the differential diagnosis.43 The main causes include
toxoplasmic chorioretinitis,44 sarcoid choroiditis,41
birdshot chorioretinopathy,45 syphilis,46 tuberculous
posterior uveitis,47 Vogt-Koyanagi-Harada (VKH)
disease,48 multifocal choroiditis,49 serpiginous
choroiditis,50 and punctate inner choroidopathy.49,51,52
UME can occur in both infectious and autoimmune
choroiditis/chorioretinitis as a complication of the
inflammatory process (Figure 1A).1 Cystic spaces
resulting from a disruption of the retinal layers deriv-
ing from direct tissue damage can also be seen and
have to be distinguished from UME which is caused
by a breakdown of the blood–retinal barrier
(Figure 1B).53,54
Choroiditis and chorioretinitis can be complicated
by inflammatory choroidal neovascularization more
often than other uveitis entities.55 The exudative pro-
cess linked to the presence of inflammatory choroidal
neovascularization often leads to the formation of
cystic changes within the retinal tissue overlying the
lesion (Figure 1C). This particular form of intraretinal
fluid is related to the inflammatory choroidal neovas-
cular activity, can be present in absence of active
inflammation, and needs a different treatment strat-
egy, often combining anti-inflammatory drugs with
anti-vascular endothelial growth factors in order to
control the neovascularization rather than the inflam-
mation alone.56
Panuveitis
Uveitis having diffuse inflammation involving the
anterior chamber, the vitreous and the retinochoroidal
region are named panuveitis.19 Majority of the times,
these entities are associated with systemic diseases
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and are accompanied by manifestations outside the
eye. The most common panuveitis are caused by
sarcoidosis,41 tuberculosis,47 Bechet’s disease,57
syphilis,46 and VKH disease.48
UME can occur in panuveitis with a variable inci-
dence which is usually directly correlated with the
duration and the amount of intraocular inflammation
(Figure 2A).1 UME is such a common finding in
chronic panuveitis that its absence in case of a chronic
inflammation of unknown origin should rise the sus-
pect of a masquerade syndrome such as an intraocu-
lar lymphoma.58
Similar to choroiditis and chorioretinitis, panuveitis
can show disruption of the retinal layers mimicking
UME and can be complicated by inflammatory choroidal
neovascularization (though it is pertinent to note that
inflammatory choroidal neovascularization may rarely
lead to intraretinal cystic changes).55 Epiretinal mem-
branes and vitreomacular tractions are also a common
complication of panuveitis as a result of the combined
vitreoretinal inflammation (Figure 2B). Such epiretinal
membranes can induce the formation of tractional UME
which can be particularly resistant to pharmacological
treatment and may require a surgical approach.13
FIGURE 1. Optical coherence tomography (OCT) scans demonstrating Cystoid macula edema in choroiditis and chorioretinitis.
(A).Cystoid macular edema (white asterisk) complicating a case of tubercular choroiditis. A choroidal granuloma (CG) is clearly
visible in the choroidal stroma in the perifoveal region along with an area of choriocapillaris hypo-perfusion (CCH) right underneath
the fovea.
(B).Cystic spaces within the retina (white asterisk) are visible along the edges of a patch of toxoplasmic chorioretinitis (white arrows).
The formation of these spaces is usually related to a direct damage to the retinal tissue structure rather than to a breakdown of the
blood–retinal barrier.(C).
Intraretinal cystic accumulation of fluid (white asterisk) as part of the exudative process secondary to the presence of an inflammatory
choroidal neovascularization (white arrowheads) in a patient affected by sarcoid chorioretinitis.
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Scleritis
Scleritis is an immune-mediated chronic inflammatory
process that involves the sclera and is often associated
with systemic disorders. Anterior scleritis is the most
common anatomical location of scleritis and can be
further classified as nodular, diffuse, necrotizing with
inflammation, and necrotizing without inflammation
(scleromalacia). Entities such as rheumatoid arthritis,
polychondritis, granulomatosis with polyangiitis, and
polyarteritis nodosa, among others, may be associated
with this condition, requiring chronic systemic therapy
with steroids and/or immunomodulatory agents.59,60
Macular edema is a rare complication of scleritis. In
a series published by Bernauer et al., of the 40 patients
with a 5-year follow-up, UME was observed in 6 eyes
(11%). The authors observed that UME was fully
reversible after high-dose oral steroids.61 Similarly,
Pavesio et al., in their review of systemic disorders
associated with scleritis, noted that UME is a rare
complication of scleritis with an increased risk of
vision loss and intraocular inflammation (sclero-
uveitis).62
DIFFERENTIAL DIAGNOSIS OF NON-
UVEITIC MACULAR EDEMA
Macular Hole and Vitreomacular Traction
Macular holes are full-thickness defects of the retinal
tissue affecting the anatomical fovea. Macular holes
are common among females with peak incidence in
the sixth-seventh decade of life. Most macular holes
are idiopathic in nature, but some may be caused due
to trauma or can be associated with myopia. It is now
widely accepted that various tangential and antero-
posterior tractional forces at the vitreoretinal interface
may play a role in the pathogenesis of macular hole.
In addition, there have been histopathological reports
that suggest cystoid changes that occur in the retinal
tissues leading to development of a full-thickness
hole.63–65
Macular holes typically present with a well-defined
rounded excavation of retinal tissue in the central
macula. However, these holes can have associated
retinal thickening, intraretinal fluid, and macular
edema. There may be an associated cuff of SRF. At
the margins of the hole, cystic changes are fairly com-
mon and these can be easily detected using OCT
imaging. Occasionally, there may be associated epir-
etinal membranes resulting in fine crinkling.64,66,67
Therefore, in the evaluation of a macular hole, it is
imperative to analyze the OCT scans carefully, espe-
cially in situations where the size of the hole is small.
Small macular holes may be missed if all the OCT
scans are not evaluated (Figure 3).
Abnormal vitreoretinal tractional forces may lead
to the development of both, macular edema as well as
macular holes. In patients with chronic macular
edema, exacerbation of centripetal vitreomacular trac-
tional forces may lead to development of macular
pseudoholes or lamellar macular holes.68 These may
occur following interventions such as intravitreal
injections of anti-VEGF agents or other drugs such
as steroid implants.68–71 Usually, such lamellar holes
develop from chronic macular edema in the presence
of abnormal vitreoretinal traction or epiretinal mem-
branes. However, lamellar holes have been shown to
form in eyes with chronic macular edema despite
complete separation of posterior hyaloid and absence
of epiretinal membranes.72 The exact mechanism of
hole development in such eyes is unclear.
Drug-Induced Maculopathies
A number of systemically administered drugs can
result in toxicity affecting various ocular tissues.
FIGURE 2. Cystoid macular edema in panuveitis.
(A).Cystoid macular edema (dotted circle) complicating a case of sarcoid panuveitis. Areas of chronic breakdown of the blood–retinal
barrier are visible on fluorescein angiography (white arrowheads).
(B).Optical coherence tomography (OCT) scan of the posterior pole showing a Diffuse cystoid macular edema with macrocyst (white
asterisk) in a patient with chronic tubercular panuveitis. A thick epiretinal membrane complicating the picture is clearly visible (white
arrows)
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Knowledge of such agents helps in identifying
patients at high risk, who can be screened periodically
for the development of retinal disease. Long-term use
of such agents may be associated with maculopathy
that predominantly affects the outer retina including
photoreceptors and vascular plexuses. Adverse events
such as maculopathy are rare and usually develop
after chronic, long-term use of drugs (usually many
months later). Hence, clinical trials that evaluate
safety and efficacy of novel therapeutic agents may
not be powered to detect such adverse drug reactions.
Often, ocular manifestations of patients on drug
therapies may be confusing due to other comorbid-
ities in the patient, which may lead the ophthalmolo-
gist to suspect infections and inflammatory
pathologies leading to UME and maculopathy rather
than toxicity due to the drug.73,74
Various drugs including antimalarial chloroquine
and hydroxychloroquine,75 topiramate,76 tacrolimus,77
antiviral agents such as ritonavir,78 tamoxifen,79
clofazimine,80 sertraline,81 deferoxamine,82
clomiphene,83 paclitaxel,84 BRAF inhibitors such as
Vemurafenib (used in melanomas),85,86 and recently,
antibiotics such as linezolid74 have been implicated in
the development of maculopathy. Maculopathies due
to these agents can present with intraretinal cystoid
spaces or SRF accumulation (except chloroquine,
hydroxychloroquine, and ritonavir). Usually, the pre-
sentation is symmetrical and bilateral (Figure 4). With
increasing number of novel drugs introduced for var-
ious clinical indications, it is imperative to monitor
long-term effects of these agents on critical tissues
such as retinal photoreceptors, the damage to which
may be irreversible.
Drug-induced maculopathies can be diagnosed
using multimodal imaging techniques such as FA
and OCT, which are able to effectively rule out infec-
tious, inflammatory, and vascular pathologies leading
to macular edema. Once drug toxicity is strongly
suspected, the offending agents can be withdrawn or
substituted. Reversal of retinal structural changes on
OCT helps clinch the diagnosis of drug toxicity.
However, with certain drugs such as chloroquine,
hydroxychloroquine, and ritonavir, the structural
changes may persist despite drug withdrawal. In
addition, electrophysiological studies aid in the detec-
tion of photoreceptor and RPE damage due to drug
intake. In cases with atypical retinal edema, and in
non-responsive cases, electrophysiological studies
help in assessing the structural damage to the RPE
and photoreceptors.
Pseudophakic and Postsurgical Macular Edema
CME following cataract surgery, also known as Irvine-
Gass syndrome, is a well-known cause of poor vision
following uneventful cataract surgery.87–89 The inci-
dence of clinical (symptomatic) pseudophakic cystoid
macular edema (PCME) has been greatly reduced
because of the advances in surgical techniques
(approximately 0.1–2.3%) including phacoemulsifica-
tion and small-incision cataract surgery.87,90 A large
FIGURE 3. Imaging using spectral-domain optical coherence tomography (SD-OCT) of a patient with vitreomacular interface
abnormalities. A vertical OCT scan passing through the macula shows presence of intraretinal cystoid spaces suggestive of cystoid
macular edema (A). However, a horizontal OCT scan passing just inferior to the fovea (B) shows presence of abnormal vitreomacular
traction (white asterisk) and retinal tissue defect (white arrow) suggestive of a full-thickness macular hole. The illustrative case shows
the importance of evaluation of each OCT B-scan to be able to arrive at the correct diagnosis.
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retrospective study including 81,984 eyes revealed that
the incidence of PCME in eyes without operative com-
plications, diabetes, or risk factors was 1.17%.91 The
incidence of clinically significant PCME peaks at
approximately 5 (4–12) weeks in a healthy population.-
90 The condition is usually self-limiting, and the reso-
lution of symptoms usually occurs within
3–12 months.
Although PCME can occur in healthy eyes with no
surgical complications, risk factors increase the like-
lihood of it occurring. Patient factors predisposing to
PCME include PCME in the contralateral eye,
African-American origin, and any risk factor that
may disrupt the blood–retinal barrier such as diabetes
mellitus, uveitis, retinal vein occlusion, retinal degen-
eration, macular degeneration, radiation retinopathy,
epiretinal membranes, choroidal tumors, prostaglan-
din analog use, and aging.87,91,92 Surgical factors
include inflammation-inducing complications such
as retained lens material, posterior capsule rupture,
vitreous loss and vitreomacular traction, and exces-
sive intraoperative manipulations such as mechanical
pupil stretch or iris prolapse during surgery, the pre-
sence of an anterior chamber intraocular lens, filtering
or other glaucoma operations, and intraocular
surgeries.87
Conventionally, PCME is classified as angiographic
(seen on FA) or clinical (associated with decreased
visual acuity) and acute (within 6 months) or chronic
(more than 6 months).93 However, OCT definitions
for CME have been recently added and the incidence
of PCME varies between 0.2% and 20%94 depending
on the definition used for diagnosis, which include
clinical, angiographic, and tomographic. The inci-
dence of CME measured by OCT is as high as
41%.95 Antcliff et al.17 compared OCT with fundus
FA for detecting PCME and found that the sensitivity
was 96% and the specificity was 100% for OCT.
Recently, many authors have reported microcystic
edema (MME) in the central macula, characterized
by isolated INL cystoid changes in the absence of
outer plexiform alterations.96–98 The incidence, risk
factors, and prophylactic response to topical nonster-
oidal anti-inflammatory drugs (NSAIDs) by MME are
very similar to those of CME. This suggests that MME
is simply a mild form of PCME.
Sometimes, it is difficult to differentiate diabetic
macular edema (DME) from PCME after cataract sur-
gery in diabetic patients. However, in order to prop-
erly treat these eyes, it is crucial to define PCME
appropriately. Pathogenesis of DME involves chronic
hyperglycemia-induced oxidative stress, impaired
blood flow, hypoxia, pericyte loss, endothelial cell
loss, downregulation of glial cell-derived neuro-
trophic factor, and blood–retinal barrier dysfunction.
On the other hand, PCME is induced by an acute and
local release of inflammatory mediators during the
surgery from lens epithelial cells and uveal tissue in
the anterior segment. If mediators diffuse to the vitr-
eous and retina, the inflammatory response will cause
FIGURE 4. Fundus photographs of the right (A) and left eyes (B) of a 62-year-old female on chronic sertraline therapy (for the past
7 months) who presented with diminution of vision in both the eyes. Fundus examination revealed presence of a dull central foveal
reflex. Spectral-domain optical coherence tomography (SD-OCT) scans of both the eyes (C and D) show presence of subretinal fluid in
both the eyes and intraretinal cystoid spaces in the left eye. The patient was diagnosed with sertraline toxicity. The offending drug
was withdrawn and the patient showed complete reversal of the maculopathy.
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local vasodilatation and disruption of the blood–ret-
inal barrier. Increased vascular permeability may lead
to fluid accumulation in the inner nuclear and outer
plexiform layers of the retina, and CME will
develop.99
Munk et al.90 described OCT criteria to differenti-
ate PCME from DME. A higher macular thickness/
retinal volume ratio, a thicker outer nuclear layer
(ONL)/Henle’s layer, solely inner nuclear layer
(INL) cysts, absence of epiretinal membrane, intact
hyper-reflective outer retinal bands, and presence of
SRF likely refer to PCME, whereas a higher ONL/INL
thickness ratio parafoveally, the presence of microa-
neurysms, hard exudates, and microfoci, the presence
of additional ganglion cell or retinal nerve fiber layer
cysts, and the absence of SRF, mainly ONL cysts, and
disruption of the photoreceptor layers are character-
istic of DME. In contrast to the PCME eyes, the major-
ity of DME eyes preserve foveal depression (Figure 5).
Disturbance of the inner blood–retinal barrier
causes a secondary choroidal thickening. Several
large-scale studies reported an increase in choroidal
thickness following uneventful small incision cataract
surgery, with maximal increase 1 month
postoperatively.100–102 Moreover, choroidal thickness
decreased in correlation with resolution of the edema.
However, even following PCME resolution, choroidal
thickness remained significantly higher in the affected
eyes compared to the fellow eyes. The finding of
increased choroidal thickness in eyes with PCME
may be explained by an alteration of the choroidal
vessels walls secondary to the inflammatory state.
This theory may be supported by reports describing
choroidal changes observed with noninfectious uvei-
tis such as VKH disease103,104 and Behçet’s disease.105
In addition, in VKH disease, inflammatory thickening
of the choroid (due to dense granulocytic infiltration)
causes development of choroidal folds. These changes
result in a delay in choriocapillaris and arterial filling,
which can be observed on FA and indocyanine green
angiography (ICGA). Secondary alterations occur in
the RPE due to choroidal hypoperfusion leading to
multiple pin-point leaks (characteristic of VKH dis-
ease), that slowly fill and lead to serous retinal
detachment.106,107
The prevention of Irvine-Gass syndrome continues
to pose challenges for ophthalmologists, due to its
ability to affect individuals without any obvious pre-
disposing factors at variable times of onset
postoperatively.108 Some studies demonstrated negli-
gible benefit with NSAID use after uncomplicated
cataract surgery in patients without risk factors,88,109
FIGURE 5. Various spectral-domain optical coherence tomography (SD-OCT) signs help distinguishing diabetic macular edema
(DME) form other causes of cystoid macular edema (CME). One of the first biomarkers of inflammation in the diabetic retina is the
intracellular swelling of the Muller cells, visible tomographically as hyperreflective retinal spots (A, yellow arrows), that can be
distinguished from hyperreflective hard exudates (B, red arrow) that are bigger and cause back-shadowing. In early stages of DME,
the appearance is ‘spongiform’ (B) and only later the cysts become well defined (C). With a progressive increase of the height of the
cysts, a snapping of the axons of the bipolar cells can happen (D, white asterisk). This causes and interruption of the visual pathway
from the photoreceptors to the nerve fibers, leading to a disorganization of the retinal inner layers (E, yellow asterisk) that accounts
for a low visual acuity despite the absence of intraretinal fluid. A second input to the disorganization of the inner retinal layers may
come from obliteration of foveal and perifoveal capillaries detected on optical coherence tomography angiography (OCTA) (F) .
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whereas others support their use in the treatment and
prophylaxis of PCME in uncomplicated cases. In sub-
jects undergoing cataract surgery, and at low risk for
PCME, the routine use of preoperative nepafenac was
suggested necessary only to achieve a faster visual
recovery.110 However, prophylactic therapy should
be considered in those with high risk like diabetic
patients especially those with diabetic retinopathy
due to the deficient blood–retinal barrier and
advanced vascular changes. Options for prevention
of macular edema after cataract surgery in patients
with non-proliferative diabetic retinopathy include
preoperative treatment with steroids, intravitreal
injections of anti-VEGFs, laser treatment, and topical
NSAIDs. It seems more prudent to prevent PCME
rather than treat it, since treatment usually involves
more invasive methods like intravitreal NSAID,111
subtenon triamcinolone,112 or intravitreal dexametha-
sone implant injections. Boscia et al. suggested that all
diabetic patients undergoing cataract surgery should
be treated with topical NSAIDs to prevent PCME.
Intravitreal anti-VEGF drugs and steroids, combined
with cataract surgery, may be considered in patients
with preexisting DME.113
The beneficial effect of prednisolone acetate eye
drops mono-therapy after cataract surgery has scar-
cely been demonstrated109,114; rather, its use has
remained a legacy of practice for over 50 years.
Corticosteroids are effective in suppressing post-
operative inflammation, but have little suppression
effect on PCME and potentially increase intraocular
pressure. In several studies, almost all PCME cases
occurred in spite of conventional postoperative topi-
cal steroid treatment including prednisolone or dex-
amethasone for 4–6 weeks. The problems with
steroids are limited penetration and adverse effects
with prolonged use like intraocular pressure spikes,
delayed wound healing, and herpes virus activation.
Due to anatomic membrane barriers and the lacrimal
drainage, it can be difficult to obtain therapeutic drug
concentrations in the posterior parts of the eye after
topical administration. However, in a recent retro-
spective chart review of 1835 who underwent phacoe-
musification and received only post-operative topical
prednisolone (721 patients) or topical dexamethasone
(414 patients) with no NSAIDS addition, the rate of
postoperative CME was, respectively, 4% and 4.1%.115
It is postulated that surgical manipulation within
the anterior chamber may lead to the release of ara-
chidonic acid from uveal tissue, with the production
of either leukotrienes via the lipoxygenase pathway
or prostaglandins via the cyclooxygenase (COX)
pathway.116 Subsequently, inflammatory mediators
diffuse posteriorly into the vitreous and disrupt the
blood–retinal barrier. This disruption results in
increased permeability of the perifoveal capillaries
and fluid accumulation within the retina.94
Treatment options correspond to many postulated
mechanisms for the formation of PCME. Shelsta and
Jampol117 suggested a stepwise algorithm for PCME
treatment. They recommended starting with the initial
combination of a topical NSAID and a topical corticos-
teroid, either asmonotherapy or combined therapy. The
role of corticosteroids in the treatment of PCME
involves the inhibition of leukotriene and prostaglan-
dins synthesis.118 Corticosteroids decrease prostaglan-
dins production by inhibiting phospholipase A2 in the
arachidonic acid cascade. In addition to their anti-
inflammatory properties, corticosteroids also inhibit
macrophage and neutrophil migration and decrease
capillary permeability and vasodilation.119 NSAIDs
work by inhibiting the COX enzymes. They are active
in the inflammatory process, catalyzing the biosynthesis
of eicosanoids from arachidonic acid to produce pros-
taglandins and thromboxanes.120 Prostaglandins within
the eye produce vasodilatation and disruption of the
blood–ocular barrier.120
For refractory cases, Benhamou et al.121 adminis-
tered repeated intravitreal triamcinolone injections,
while Bellocq et al.122 assessed the effectiveness of
intravitreal dexamethasone implants (the EPISODIC
study). They found that more than half of the patients
who were followed-up for at least 1 year presented
neither a functional nor an anatomical recurrence.
Falavarjani et al.123 reviewed the use of intravitreal
bevacizumab injection for the treatment of PCME.
They did not find any high-quality evidence to recom-
mend anti-vascular endothelial growth factor agents
as a routine treatment for PCME. However, they con-
cluded that bevacizumab injection can be considered
in patients with refractory PCME that is unresponsive
to intravitreal steroids.
Diabetic Macular Edema
DME is a major public health concern, representing
the major cause of visual loss in individuals with
diabetic retinopathy. The pathogenesis of DME is
multifactorial and complex, but this downstream cas-
cade of events is reflected into the SD-OCT biomar-
kers and appearances of DME that can help
distinguish it from other causes of CME.
Chronic hyperglycemia induces overproduction of
superoxide by the mitochondrial electron transport
chain124 and this excess production of reactive oxygen
species (ROS) can be the upstream event leading to
DME. Evidences have demonstrated that nitric oxide
produced by the ROS appears to have a predominant
role in leukostasis. Increased leukostasis has been
correlated with increased expression of intercellular
adhesion molecule-1 and vascular leakage125,126 that
lead to a breakdown of the blood–retinal barrier. An
altered blood–retinal barrier implies an increase in the
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inflammatory response, and the release of inflamma-
tory cytokines causes an intracytoplasmic swelling of
the Muller cells, the glial elements of the retina. This
swelling causes a release of permeability disturbing
substances from the Muller cells, such as VEGF. VEGF
plays an important role in the alteration of vascular
permeability and development of DME.
Swollen Muller cells are often the first SD-OCT bio-
marker in patients with diabetic retinopathy without
DME, and they appear as small, sometimes punctiform,
reflective lesions, visible on SD-OCT in both inner retina
and outer retina (hyperreflective retinal spots, HRS).
Coscas et al.127 were the first to describe small, puncti-
form hyper-reflective elements, scattered throughout all
retina layers, but mostly in the outer retina, in age-
related macular degeneration (AMD). These authors
interpreted HRS as activated microglial cells in late-
stage AMD. Lad et al. documented microglia involve-
ment by immunohistochemistry in human autopsy eyes
with late-stage AMD (geographic atrophy and choroi-
dal neovascularization). Madeira et al.128 reported
microglial activation in different retinal degenerative
diseases (including diabetic retinopathy) contributing
to chronic neuro-inflammation, with release of pro-
inflammatory mediators (by activated microglial cells)
and increased oxidative stress.128,129 These activated
microglial cells could be visualized in the retina as
HRS, by SD-OCT.127,130,131 Vujosevic et al.130 reported
the increase in HRS in diabetic patients versus normal
subjects (even in diabetic eyes without any clinical sign
of retinopathy), suggesting that HRS may represent
aggregates of activated microglial cells that migrate,
with the progressing of the disease, confirming pre-
vious histopathologic findings. These HRS are quite
unique of AMD and DME and have been rarely
described in UME.
HRS that may represent swollen Muller cells can be
distinguished from hard exudates since the latter have
a larger size (>30 mm), higher reflectivity (similar to
RPE–Bruch complex), and with back shadowing.
From intraretinal edema of the Muller cells, contin-
uous inflammation and the breakdown of the blood–
retinal barrier lead to extracellular edema and frank
DME. SD-OCT images of DME depict the presence of
low intraretinal reflectivity, due to fluid accumulation
in the extracellular space of the retina. The process
begins as increased thickening with sponge-like
appearance of retinal layers and later advancing to
the typical image of cystoid spaces.
When there is a situation of breakdown of the
blood–retinal barrier, the Starling law governing the
movements of fluid applies.132 Any change in the
equilibrium between hydrostatic, oncotic, and osmo-
tic pressure gradients across the retinal vessels con-
tributes to further water movements and may result
in increased edema formation. An increase in Pplasma
(hydrostatic pressure) due to increased systemic
blood pressure does contribute to retinal edema for-
mation when there is a breakdown of the blood–ret-
inal barrier. A decrease in Ptissue (osmotic pressure) is
also an important component: any alteration in the
cohesion of the retinal tissue due to pathologies, such
as vitreous traction with pulling on the inner limiting
membrane of the retina will lead to a decrease in
Ptissue thus facilitating fluid accumulation in the
retina. Extravagation of proteins and lipoproteins,
such as in hard exudates, increase the oncotic pres-
sure in the retinal tissue and draw more water in the
retinal extracellular space contributing to a progres-
sive increase in retinal edema.
In larger intraretinal cysts, the tissue that connects the
retinal photoreceptors to the ganglion cells consists
mainly of bipolar cells. Pelosini et al.133 suggested that if
edema increases retinal thickness beyond an elastic limit,
bipolar axons can snap and cause loss of visual informa-
tion signaling fromphotoreceptors to ganglion cells. This
bipolar destruction may not be completely reversible,
accounting for disorganization of retinal inner layers
(DRIL) on SD-OCT.134 DRIL is a novel OCT parameter
characterized by the inability to distinguish boundaries
between inner layers on SD-OCT that may have an effect
on the visual outcomes of patients with DME.
More than 55% of patients with diabetes with macu-
lar edema and about 70% of those with clinically sig-
nificant macular edema have simultaneous macular
ischemia.135 Both capillary non-perfusion and capillary
closure are the result of retinal microthombosis.
Increased platelet adhesiveness and aggregation in
DME seem to be secondary to alteration in endothelial
integrity and increase in inflammatory cytokines.
OCT angiography (OCTA), a novel non-invasive
dye-less technique of angiographic imaging of the
retina and choroid, can detect microcirculation
impairment in the macula even before clinically
apparent retinopathy develops. In eyes with DME
and diabetic retinopathy, OCTA seems to better
delineate the foveal avascular zone and areas of
flow impairment when compared with FA.
Spaide136 described flow voids in the deep vascular
plexus that were topographically associated with
the cystoid spaces. Flow voids were also seen in
the superficial plexus but to a lesser extent.
Similarly, microaneuryms were found in both
plexuses but more frequently in the deep vascular
plexus. Many of these microaneurysms were adja-
cent to the cystoid spaces, suggesting that the
major contributors to DME are the microaneur-
ysms in the deep capillary plexus. Macular ische-
mia may be a cause of visual acuity loss and it has
been suggested that DRIL is strongly correlated
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with non-perfusion areas.134 Because there is some
evidence showing that retinal vessels can re-per-
fuse after the resolution of DME, OCTA imaging of
patients with DRIL may help to identify a thresh-
old for capillary loss that will result in DRIL and
poor visual outcome.
Vascular Macular Edema
A number of clinical entities can lead to development of
choroidal ischemia, such as systemic hypertension, preg-
nancy-induced hypertension, pre-eclampsia, and vascu-
litic causes such as giant cell arteritis, among others.
These patients may have normal retinal circulation and
a normal-looking fundus, but deficits in the choroidal
perfusion which may be detectable only using FA. Such
causes of choroidal ischemia, though rare, may be asso-
ciated with serous retinal detachment and accumulation
of SRF, mimicking UME. The mechanism of develop-
ment of serous retinal detachment may be related to the
dysfunction and disturbance of the RPE function due to
lack of choroidal perfusion.137
Conditions associated with significantly thickened
choroid, such as VKH disease, may also demonstrate
choroidal hypoperfusion. In a study by Fardeau et al.,
FA, ICGA, andOCT characteristics of patients with VKH
disease were performed at various stages of the disease.
A total of 13 patients with early active disease had bilat-
eral serous retinal detachment. The authors observed
choriocapillaris filling delay in all 13 patients, and arterial
filling delay on ICGA in 10 patients, and decreased chor-
oidal vessels in 9 patients. Thus, the authors concluded
that choroidal hypoperfusion due to significantly thick-
ened choroid resulted in dye leakage through the abnor-
mal RPE cells into the subretinal space caused by
ischemic damage.106 Thus, generalized abnormalities of
the choroidal vasculature may be rare associated with
serous retinal detachments similar to UME.
Tumoral Macular Edema
Certain intraocular tumorsmay be rarely associatedwith
retinal edema,macular thicknening, and accumulation of
serous SRF. The mechanism of development of macular
edema could be immune-mediated inflammatory
changes at the macula, or due to deposition of tumor
cells leading to local changes in the milieu such as altera-
tions in the oncotic pressure, causing fluid accumulation.
Precise mechanisms of development of retinal edema
are, however, still not precisely known. Although rare,
macular edema may develop in such conditions, and
early diagnosis is only possible if a differential diagnosis
is considered and high clinical suspicion is maintained.
Intraocular lymphomas are important causes of mas-
querades because they can present with protean
manifestations, such as vitritis, retinal vasculitis, hypop-
yon uveitis, or even macular edema.138–140 Fardeau et al.
compared the clinical, angiographic, and tomographic
characteristics of 244 consecutive patients with severe
posterior uveitis who underwent vitreous biopsy for
cytological analysis. The authors obtained 53 positive
samples for intraocular lymphoma (non-Hodgkin’s
type) and 191 without any tumor cells. While macular
edema was less common among subjects with non-
Hodgkin’s lymphoma compared to patients without
intraocular tumor (11.3% versus 19.9%), the p value was
not significant (p = 0.217).58 Thus, among patients with
macular edema, and especially those with nodular
hyper-reflective lesions in the RPE, intraocular lym-
phoma should be considered.
Deposition of tumor cells and resultant local changes
may also lead to accumulation of fluid in the macula,
simulating UME. For instance, Kim et al. reported a case
of acute lymphoblastic leukemia in a 45-year-old woman
which presented with bilateral serous retinal detach-
ments leading to central scotoma in both the eyes, but
no systemic manifestations. The authors postulated that
serous retinal detachment in these patients may occur
due to choroidal involvement by leukemic cells causing
dysfunction of the RPE and breakdown of the blood–
retinal barrier.141 In another case by Izzedine et al, bilat-
eral serous retinal detachment in a 48-year-old male led
to the diagnosis of nephrotic syndrome. Further study of
the renal biopsy revealed the presence of amyloid light
chain deposits.142
CONCLUSIONS AND SUMMARY
Anumber of uveitic andnon-uveitic entitiesmay result in
development of macular edema due to activation of var-
ious pro-inflammatory pathways and breakdown of
blood–retinal barrier. UME can occur as a complication
or an associated feature of all forms of uveitis including
AUand retinal vasculitis. In addition, variousnon-uveitic
entities such as diabetes, vein occlusions, postoperative
(following cataract surgery), and drug intake may be
associated with development of macular edema. It is
imperative to obtain a detailed medical and surgical his-
tory, and perform a detailed ophthalmic evaluation to
determine the cause of UME. Imaging modalities such
as FA and OCT are very useful in identifying the cause
and extent of the pathology. Thus, various possibilities
and differential diagnosis must be kept in mind during
the assessment of patients with UME.
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